Telerehabilitation Versus Face-to-Face LSVT BIG in Individuals With Parkinson Disease
9. juni 2026 opdateret af: Bezmialem Vakif University
The Effects of Telerehabilitation and Face-to-Face LSVT BIG Method on Motor and Non-Motor Symptoms in Individuals With Parkinson Disease
This prospective, randomized controlled trial will enroll 40 individuals with idiopathic PD (Hoehn & Yahr stages 1-3, MoCA ≥21). Participants will be randomly assigned in a 1:1 ratio to either a telerehabilitation LSVT BIG group or a face-to-face LSVT BIG group, with randomization stratified by Hoehn & Yahr stage using a computer-based block randomization system. Both groups will receive the standard LSVT BIG® protocol consisting of 16 sessions over four weeks (4 days/week, 1 hour/session). Treatment content will include maximal daily exercises, functional component tasks, "big" gait training, and individually tailored hierarchy tasks. The telerehabilitation group will receive all sessions via synchronous video conferencing under physiotherapist supervision, while the face-to-face group will receive sessions in a clinical setting. Both groups will be assigned home exercise programs in accordance with the LSVT BIG® protocol, and treatment adherence will be monitored throughout the study.
Outcomes will be assessed at baseline, after 4 weeks of treatment, and at 6-month follow-up. Primary outcomes include postural stability and fall risk assessed with the Biodex Balance System (anterior-posterior stability index, mediolateral stability index, general stability index, fall risk index, limits of stability) and motor and non-motor symptom severity assessed with the MDS-UPDRS (Parts I, II, and III). Secondary outcomes include dynamic balance (Mini-BESTest), functional mobility (Timed Up and Go Test, 10-Meter Walk Test), quality of life (PDQ-39), depression (Beck Depression Inventory), sleep quality (Parkinson's Disease Sleep Scale), fatigue (Parkinson Fatigue Scale), cognitive function (MoCA), and treatment satisfaction (Global Rating of Change Scale).
Studieoversigt
Status
Ikke rekrutterer endnu
Intervention / Behandling
Undersøgelsestype
Interventionel
Tilmelding (Anslået)
40
Fase
- Ikke anvendelig
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
- Barn
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Ingen
Beskrivelse
Inclusion Criteria:
- Diagnosis of idiopathic Parkinson's disease
- Hoehn and Yahr stage 1-3
- Montreal Cognitive Assessment (MoCA) score ≥ 21
- Ability to use a smartphone, tablet, or computer
- Access to internet connection and basic digital literacy
- Participation in activities outside the home at least 3 days per week
Exclusion Criteria:
- Diagnosis of a neurological condition other than idiopathic Parkinson's disease
- Change in antiparkinsonian medication regimen during the study period
- History of deep brain stimulation
- Visual or hearing impairment that would prevent participation in treatment or assessments
- Severe cardiovascular, orthopedic, pulmonary, or systemic comorbidity contraindicating exercise
- Diagnosis of severe depression, psychotic disorder, or uncontrolled psychiatric illness
- Participation in another structured physiotherapy or rehabilitation program for
- Parkinson's disease within the last three months
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Face-to-Face LSVT BIG
Participants will receive the standard LSVT BIG® protocol delivered in a clinical setting.
The protocol consists of 16 sessions over four weeks (4 days/week, 1 hour/session), including maximal daily exercises, functional component tasks, "big" gait training, and individually tailored hierarchy tasks.
Home exercise assignments will be provided in accordance with the standard LSVT BIG® protocol.
|
The standard LSVT BIG® protocol will be delivered in a clinical setting by a certified physiotherapist.
The protocol consists of 16 sessions over four weeks (4 days/week, 1 hour/session).
Treatment content includes maximal daily exercises, functional component tasks, "big" gait training, and individually tailored hierarchy tasks.
Home exercises will be assigned on treatment days (once) and non-treatment days (twice daily) in accordance with the standard LSVT BIG® protocol.
|
|
Aktiv komparator: Telerehabilitation LSVT BIG
Participants will receive the standard LSVT BIG® protocol delivered via synchronous video conferencing under physiotherapist supervision.
The protocol consists of 16 sessions over four weeks (4 days/week, 1 hour/session), including maximal daily exercises, functional component tasks, "big" gait training, and individually tailored hierarchy tasks.
Home exercise assignments will be provided in accordance with the standard LSVT BIG® protocol.
|
The standard LSVT BIG® protocol will be delivered via synchronous video conferencing under physiotherapist supervision.
The protocol consists of 16 sessions over four weeks (4 days/week, 1 hour/session).
Treatment content includes maximal daily exercises, functional component tasks, "big" gait training, and individually tailored hierarchy tasks.
Home exercises will be assigned on treatment days (once) and non-treatment days (twice daily) in accordance with the standard LSVT BIG® protocol.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Biodex Balance System
Tidsramme: Baseline, Week 4, Month 6
|
Baseline, Week 4, Month 6
|
|
|
Movement Disorder Society-Unified Parkinson's Disease Rating Scale
Tidsramme: Baseline, Week 4, Month 6
|
Motor and non-motor symptom severity will be assessed using Parts I, II, and III of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale.
Part I evaluates non-motor symptoms, Part II evaluates motor aspects of daily living, and Part III evaluates clinician-rated motor signs.
Each item is scored from 0 (normal) to 4 (severe), with higher total scores indicating greater symptom severity.
|
Baseline, Week 4, Month 6
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Mini-Balance Evaluation Systems Test
Tidsramme: Baseline, Week 4, Month 6
|
Dynamic balance will be assessed using the 14-item Mini-Balance Evaluation Systems Test, evaluating postural responses, anticipatory postural adjustments, dynamic gait, and sensory orientation.
Each item is scored from 0 to 2, with a maximum total score of 28.
Higher scores indicate better balance performance.
|
Baseline, Week 4, Month 6
|
|
Timed Up and Go Test
Tidsramme: Baseline, Week 4, Month 6
|
Functional mobility and dynamic balance will be assessed by measuring the time (in seconds) required to rise from a chair, walk 3 meters, turn, and return to sitting.
Longer completion times indicate poorer functional mobility.
|
Baseline, Week 4, Month 6
|
|
Parkinson's Disease Questionnaire-39
Tidsramme: Baseline, Week 4, Month 6
|
Health-related quality of life will be assessed using the 39-item Parkinson's Disease Questionnaire-39, covering 8 domains.
Each item is scored from 0 to 4, with domain scores ranging from 0 to 100.
Higher scores indicate worse quality of life.
|
Baseline, Week 4, Month 6
|
|
Beck Depression Inventory
Tidsramme: Baseline, Week 4, Month 6
|
Depressive symptoms will be assessed using the 21-item Beck Depression Inventory.
Each item is scored from 0 to 3, with total scores ranging from 0 to 63.
Higher scores indicate greater severity of depressive symptoms.
|
Baseline, Week 4, Month 6
|
|
Parkinson's Disease Sleep Scale
Tidsramme: Baseline, Week 4, Month 6
|
Sleep quality and sleep-related disturbances will be assessed using the 15-item Parkinson's Disease Sleep Scale.
Each item is scored on a visual analog scale from 0 to 10. Lower total scores indicate poorer sleep quality.
|
Baseline, Week 4, Month 6
|
|
Parkinson Fatigue Scale
Tidsramme: Baseline, Week 4, Month 6
|
Fatigue severity and its impact on daily functioning will be assessed using the 16-item Parkinson Fatigue Scale.
Each item is scored from 1 to 5, with higher total scores indicating greater fatigue.
|
Baseline, Week 4, Month 6
|
|
Montreal Cognitive Assessment
Tidsramme: Baseline, Week 4, Month 6
|
Cognitive function will be assessed using the Montreal Cognitive Assessment, evaluating attention, executive functions, memory, language, visuospatial skills, abstract thinking, and orientation.
Total scores range from 0 to 30, with higher scores indicating better cognitive performance.
|
Baseline, Week 4, Month 6
|
|
Global Rating of Change Scale
Tidsramme: Week 4, Month 6
|
Patient-perceived change in overall condition will be assessed using the Global Rating of Change Scale.
Scores range from -2 (much worse) to +2 (much better), with higher scores indicating greater perceived improvement.
|
Week 4, Month 6
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Samarbejdspartnere
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Anslået)
20. juni 2026
Primær færdiggørelse (Anslået)
30. december 2027
Studieafslutning (Anslået)
30. juni 2028
Datoer for studieregistrering
Først indsendt
2. juni 2026
Først indsendt, der opfyldte QC-kriterier
2. juni 2026
Først opslået (Faktiske)
5. juni 2026
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
11. juni 2026
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
9. juni 2026
Sidst verificeret
1. juni 2026
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- E-83460662-050.04-1593414
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .